Neal Shore, MD, FACS, analyzes a patient case involving a 75-year-old man with non-metastatic castration-resistant prostate cancer (nmCRPC) and explores recent trials that offer insights into patient sequencing and treatment selection for this condition.
Stephen T. Oh, MD, PhD, presents the case of a 63-year-old patient with myelofibrosis, discusses the clinical use of JAK inhibitors, and provides insights on the overall treatment landscape.
Dr. Robert Motzer shares his clinical perspectives and insights on the management of patients with nccRCC, including initial therapy considerations, emerging data on combination regimens, adverse events and the future landscape.
John O. Mascarenhas, MD, presents the case of a 62-year-old man with myelofibrosis and offers clinical insights on treatment options, with a focus on JAK2 inhibitors.
Expert Hans Hammers, MD, reviews a case of a 59-year-old African American woman who underwent nephrectomy for left renal mass revealing clear cell RCC, who later developed metastatic disease managed initially with pembrolizumab and lenvatinib.
An oncologist's expert review of a 42-year-old woman diagnosed with KRAS G12C mutated lung adenocarcinoma, providing insights into optimal treatment recommendations based on current evidence and guidelines.
Marcia S. Brose, PhD, MD, presents the case of a 43-year-old man with radioiodine-refractory differentiated thyroid cancer (RAI-R-DTC) and discusses treatment practices.
Brooke Peters, PharmD, BCOP, shares her insight on institutional program development and operationalizing of bispecifics administration, highlighting its key components, roles involved, and clinical consideration for the management of related toxicities.
Virginia Kaklamani, MD, presents the case of a woman with HR+/HER2- metastatic breast cancer and discusses the potential treatment approaches.
Expert Douglas Sborov, MD, MS, presents the case of a 54-year-old woman with newly diagnosed multiple myeloma and provides clinical insights on treatment.
David Zhen, MD, reviews the case of a 60-year-old man with stage IV gastric adenocarcinoma and discusses ongoing research and the evolving treatment landscape.
Sandip P. Patel, MD, a medical oncologist, reviews the case of a 60-year-old woman with early-stage non–small cell lung cancer and provides clinical insights on treatment practices.
Lori Wirth, MD, reviews the case of a 64-year-old woman with differentiated thyroid cancer (DTC) and provides clinical insights on the treatment landscape for patients with radioiodine-refractory disease.
Expert Matthew Lunning, DO, FACP, reviews the case of a 73-year-old woman with R/R DLBCL, considering current and emerging treatment strategies in this setting.
Michael B Atkins, MD, discusses first-line treatment options for a patient with stage IV BRAF-mutated melanoma. He also reviews data that may help guide treatment and sequencing decisions for patients with metastatic melanoma.
Joshua K. Sabari, MD, reviews the case of a 73-year-old with EGFR+ non–small cell lung cancer and provides comprehensive insights on the evolving treatment landscape.
Justin LaPorte, PharmD, BCOP, discusses the administration of bispecific antibodies and the coordination between academic and community centers.
Expert Matthew Lunning, DO, FACP, reviews the case of a 67-year-old man with R/R DLBCL and considers optimal treatment strategies in this setting.
Anthony Hunter, MD, presents the case of a 76-year-old woman with newly diagnosed myelofibrosis for discussion and reviews the available treatment options, including the recently FDA approved JAK inhibitor momelotinib.
Matthew L. Ulrickson, MD, discusses the diagnosis, treatment, and future therapeutic landscape of relapsed/refractory BPDCN, addressing unmet needs and promising therapies in this rare disease.
Rafael Fonseca, MD, discusses treatment considerations for a 66-year-old man with relapsed/refractory multiple myeloma after several prior therapies, and highlights recent clinical trial results with novel BCMA-targeted bispecific antibodies and other therapies in the relapsed/refractory setting.
Centering discussion on a patient case of relapsed/refractory multiple myeloma, expert David Dingli, MD, PhD, reflects on the current treatment paradigm and evolving management strategies in this setting.
Expert Matthew Lunning, DO, FACP, reviews a patient case of diffuse large b-cell lymphoma and considers how the evolving treatment paradigm has impacted clinical practice.
Expert insight into optimal diagnosis and management strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN) centered around a hypothetical patient case.
Centering discussion on a patient case of metastatic non–small cell lung cancer, expert Sandip P. Patel, MD, provides insight into updated research and treatment strategies with immunotherapeutic and targeted agents.
Expert gynecologic oncologist Ramez N. Eskander, MD, reviews the diagnosis and management of a 67-year-old woman with metastatic cervical cancer.
Hussein Tawbi, MD, PhD, discusses recent study updates and advances in the treatment of melanoma through the context of two patient cases.
Ajai Chari, MD, presents the case of a woman with relapsed/refractory multiple myeloma and discusses the available treatment options for patients with more than 4 prior lines of therapy, referencing recent key clinical trial data.